<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01236001</url>
  </required_header>
  <id_info>
    <org_study_id>SP1021</org_study_id>
    <nct_id>NCT01236001</nct_id>
  </id_info>
  <brief_title>Belgian Drug-utilization Study to Evaluate the Use of VIMPAT® as Adjunctive Treatment of Partial Onset Seizures in Subjects Aged 16 and Older</brief_title>
  <official_title>Multi-center, Observational, Drug-utilization Study in Belgium to Evaluate the Use of VIMPAT® in Clinical Practice as Adjunctive Treatment of Partial Onset Epilepsy in Subjects Aged 16 and Older.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Observational study at the request of the Belgian Institut National d'Assurance
      Maladie-Invalidité / Rijksinstituut voor Ziekte-en Invaliditeits Verzekering INAMI/RIZIV:

        -  type of patient treated with VIMPAT®

        -  VIMPAT® dose

        -  Effect of VIMPAT® on evolution of seizure control

        -  Persistence rate at 6 months in terms of treatment duration

        -  Discontinuation rate

        -  Description of any changes in other epilepsy therapies

        -  Safety and tolerability
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Total Daily Dose of VIMPAT® (mg) at Baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>Mean total daily dose at baseline will be only provided for subjects who were already treated by VIMPAT® at Baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Total Daily Dose of VIMPAT® (mg) at 3 Months</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Total Daily Dose of VIMPAT® (mg) at 6 Months</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Galenic Formulation Repartition in Subjects Treated by VIMPAT® at Baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>This outcome will be only provided for subjects who were already treated by VIMPAT® at Baseline.
VIMPAT is available as tablet and oral solution formulation in Belgium. The use of each galenic formulation will be presented with number of subjects by formulation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Galenic Formulation Repartition in Subjects Treated by VIMPAT® at 3 Months</measure>
    <time_frame>3 months</time_frame>
    <description>VIMPAT is available as tablet and oral solution formulation in Belgium. The use of each galenic formulation will be presented with number of subjects by formulation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Galenic Formulation Repartition in Subjects Treated by VIMPAT® at 6 Months</measure>
    <time_frame>6 months</time_frame>
    <description>VIMPAT is available as tablet and oral solution formulation in Belgium. The use of each galenic formulation will be presented with number of subjects by formulation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Who Received Concomitant Antiepileptic Drug Treatment</measure>
    <time_frame>From baseline to study termination (6 months)</time_frame>
    <description>Concomitant antiepileptic drug (AED) treatments are defined as treatments which started after or at the date of the first administration of VIMPAT®.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Persistence of VIMPAT® After 6 Months</measure>
    <time_frame>&gt;=6 months</time_frame>
    <description>Treatment persistence is defined as the percentage of subjects being treated under VIMPAT® after a given duration (&gt;=6 months).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects by Category of Clinical Evolution of Seizure Control at Baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>This outcome will be only provided for subjects who were already treated by VIMPAT® at Baseline.
Clinical evolution of seizures following administration of VIMPAT compared to baseline before start of VIMPAT. The evolution of seizure control is subjectively assessed by the investigator on a four categorical scale, with options being 1=worsened, 2=stable, 3=improved, 4=much improved. If seizure control is worse, the investigator will try to document the reason.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects by Category of Clinical Evolution of Seizure Control at 3 Months</measure>
    <time_frame>3 months</time_frame>
    <description>Clinical evolution of seizures following administration of VIMPAT compared to baseline before start of VIMPAT. The evolution of seizure control is subjectively assessed by the investigator on a four categorical scale, with options being 1=worsened, 2=stable, 3=improved, 4=much improved. If seizure control is worse, the investigator will try to document the reason.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects by Category of Clinical Evolution of Seizure Control at 6 Months</measure>
    <time_frame>6 months</time_frame>
    <description>Clinical evolution of seizures following administration of VIMPAT compared to baseline before start of VIMPAT. The evolution of seizure control is subjectively assessed by the investigator on a four categorical scale, with options being 1=worsened, 2=stable, 3=improved, 4=much improved. If seizure control is worse, the investigator will try to document the reason</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">192</enrollment>
  <condition>Seizures</condition>
  <arm_group>
    <arm_group_label>Vimpat® treatment</arm_group_label>
    <description>Patients who started VIMPAT® treatment before enrollment and patients who started VIMPAT® on/after enrollment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lacosamide</intervention_name>
    <arm_group_label>Vimpat® treatment</arm_group_label>
    <other_name>VIMPAT®</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Routine clinical practice of neurologist / neuropsychiatrist / neurosurgeon /
        neuropediatrician Sampling based upon request by the Belgian reimbursement authorities:
        request to report on 100 patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  An Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved
             written Informed Consent form

          -  Subject/legal representative is considered reliable and capable of adhering to the
             medication intake according to the judgement of the investigator

          -  Based on the investigators clinical judgement, the subjects' seizure activity is
             uncontrolled on current therapy and it is in the subjects' best interest to be
             prescribed an antiepileptic drug (AED) as adjunctive therapy. The choice to prescribe
             VIMPAT® as adjunctive therapy is made by the treating investigator

          -  The subject is aged 16 or older

          -  The subject has a diagnosis of epilepsy with partial-onset seizures according to the
             label

          -  The subject has a medication history with at least 3 AED therapies (lifetime and/or
             concomitant) with treatment failure: due to insufficient efficacy, due to significant
             adverse events

          -  Sufficient data on the clinical situation before start of VIMPAT® and information on
             VIMPAT® dosing are present in the subject's medical record for patients on treatment
             with VIMPAT® at the time of enrollment into the study

        Exclusion Criteria:

          -  The subject has previously participated in this study or has participated in a
             clinical trial within the last 2 months

          -  The subject has a history of chronic alcohol or drug abuse within the last 6 months

          -  The subject has any medical or psychiatric condition that, in the opinion of the
             investigator, could jeopardize or would compromise the subject's ability to
             participate in this study

          -  The subject has a known hypersensitivity and/or allergy to soya, peanuts, or any
             component of VIMPAT®

          -  The subject is pregnant or lactating

          -  The subject has a known AV-block degree 2 or 3

          -  The subject is expected to be insufficiently compliant with contraception.

          -  The subject has a history of suicide attempt, has received professional counseling for
             suicidal ideation, or is currently experiencing active suicidal ideation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Clinical Trial Call Center</last_name>
    <role>Study Director</role>
    <affiliation>+1 877 822 9493 (UCB)</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Aalst</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Antwerpen</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Assebroek</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brugge</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charleroi</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Duffel</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hasselt</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Louviere</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Liege</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marche-en-Famenne</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mons</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montegnée - Liege</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ottignies-Louvain-la-Neuve</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yvoir</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <removed_countries>
    <country>France</country>
  </removed_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 5, 2010</study_first_submitted>
  <study_first_submitted_qc>November 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 8, 2010</study_first_posted>
  <results_first_submitted>May 13, 2013</results_first_submitted>
  <results_first_submitted_qc>August 6, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 8, 2013</results_first_posted>
  <last_update_submitted>August 6, 2013</last_update_submitted>
  <last_update_submitted_qc>August 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lacosamide</keyword>
  <keyword>Vimpat®</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Seizures</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lacosamide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This observational study began enrollment in September 2010. The last patient visit occurred in March 2012. There were 22 study sites in Belgium.</recruitment_details>
      <pre_assignment_details>The Safety Set (SS) and Full Analysis Set (FAS) both consisted of 192 subjects. The SS consisted of all enrolled subjects who received at least one dose of VIMPAT (before or during the study). The FAS consists of all enrolled subjects.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Patients Treated With VIMPAT® Prior to Enrollment</title>
          <description>Patients who started VIMPAT® treatment before enrollment.</description>
        </group>
        <group group_id="P2">
          <title>Patients Who Started VIMPAT® Treatment on/After Enrollment</title>
          <description>Patients who started VIMPAT® treatment on/after enrollment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="105"/>
                <participants group_id="P2" count="87"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="87"/>
                <participants group_id="P2" count="65"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Incompliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Planned Visit After End of Study</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The Safety Set (SS) consists of all enrolled subjects who received at least one dose of VIMPAT® (before or during the study).
The SS was used to analyze demographic data and baseline characteristics.</population>
      <group_list>
        <group group_id="B1">
          <title>Patients Treated With VIMPAT® Prior to Enrollment</title>
          <description>Patients who started VIMPAT® treatment before enrollment.</description>
        </group>
        <group group_id="B2">
          <title>Patients Who Started VIMPAT® Treatment on/After Enrollment</title>
          <description>Patients who started VIMPAT® treatment on/after enrollment.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="105"/>
            <count group_id="B2" value="87"/>
            <count group_id="B3" value="192"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="97"/>
                    <measurement group_id="B2" value="81"/>
                    <measurement group_id="B3" value="178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.1" spread="13.4"/>
                    <measurement group_id="B2" value="43.3" spread="14.0"/>
                    <measurement group_id="B3" value="41.5" spread="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="105"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Total Daily Dose of VIMPAT® (mg) at Baseline</title>
        <description>Mean total daily dose at baseline will be only provided for subjects who were already treated by VIMPAT® at Baseline.</description>
        <time_frame>Baseline</time_frame>
        <population>Of the 192 subjects in the Safety Set (SS), 105 subjects were treated with Vimpat at Baseline are included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients Treated With VIMPAT® Prior to Enrollment</title>
            <description>Patients who started VIMPAT® treatment before enrollment.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Total Daily Dose of VIMPAT® (mg) at Baseline</title>
          <description>Mean total daily dose at baseline will be only provided for subjects who were already treated by VIMPAT® at Baseline.</description>
          <population>Of the 192 subjects in the Safety Set (SS), 105 subjects were treated with Vimpat at Baseline are included in this analysis.</population>
          <units>mg/day of Vimpat</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="272.1" spread="114.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Total Daily Dose of VIMPAT® (mg) at 3 Months</title>
        <time_frame>3 months</time_frame>
        <population>Of the 192 subjects in the Safety Set (SS), 137 subjects had Vimpat daily dosing information available at the 3-month visit and are included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients Treated With VIMPAT® Prior to Enrollment</title>
            <description>Patients who started VIMPAT® treatment before enrollment.</description>
          </group>
          <group group_id="O2">
            <title>Patients Who Started VIMPAT® Treatment on/After Enrollment</title>
            <description>Patients who started VIMPAT® treatment on/after enrollment.</description>
          </group>
          <group group_id="O3">
            <title>Total Population</title>
            <description>Patients who started VIMPAT® treatment before enrollment and patients who started VIMPAT® on/after enrollment.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Total Daily Dose of VIMPAT® (mg) at 3 Months</title>
          <population>Of the 192 subjects in the Safety Set (SS), 137 subjects had Vimpat daily dosing information available at the 3-month visit and are included in this analysis.</population>
          <units>mg/day of Vimpat</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="63"/>
                <count group_id="O3" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="316.2" spread="106.7"/>
                    <measurement group_id="O2" value="211.1" spread="77.4"/>
                    <measurement group_id="O3" value="267.9" spread="107.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Total Daily Dose of VIMPAT® (mg) at 6 Months</title>
        <time_frame>6 months</time_frame>
        <population>Of the 192 subjects in the Safety Set (SS), 154 subjects had Vimpat dosing data available at the 6-month visit and are included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients Treated With VIMPAT® Prior to Enrollment</title>
            <description>Patients who started VIMPAT® treatment before enrollment.</description>
          </group>
          <group group_id="O2">
            <title>Patients Who Started VIMPAT® Treatment on/After Enrollment</title>
            <description>Patients who started VIMPAT® treatment on/after enrollment.</description>
          </group>
          <group group_id="O3">
            <title>Total Population</title>
            <description>Patients who started VIMPAT® treatment before enrollment and patients who started VIMPAT® on/after enrollment.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Total Daily Dose of VIMPAT® (mg) at 6 Months</title>
          <population>Of the 192 subjects in the Safety Set (SS), 154 subjects had Vimpat dosing data available at the 6-month visit and are included in this analysis.</population>
          <units>mg/day of Vimpat</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="329.9" spread="119.5"/>
                    <measurement group_id="O2" value="262.7" spread="103.9"/>
                    <measurement group_id="O3" value="300.6" spread="117.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Galenic Formulation Repartition in Subjects Treated by VIMPAT® at Baseline</title>
        <description>This outcome will be only provided for subjects who were already treated by VIMPAT® at Baseline.
VIMPAT is available as tablet and oral solution formulation in Belgium. The use of each galenic formulation will be presented with number of subjects by formulation.</description>
        <time_frame>Baseline</time_frame>
        <population>Of the 192 subjects in the Safety Set (SS), 105 subjects were treated with Vimpat at Baseline are included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients Treated With VIMPAT® Prior to Enrollment</title>
            <description>Patients who started VIMPAT® treatment before enrollment.</description>
          </group>
        </group_list>
        <measure>
          <title>Galenic Formulation Repartition in Subjects Treated by VIMPAT® at Baseline</title>
          <description>This outcome will be only provided for subjects who were already treated by VIMPAT® at Baseline.
VIMPAT is available as tablet and oral solution formulation in Belgium. The use of each galenic formulation will be presented with number of subjects by formulation.</description>
          <population>Of the 192 subjects in the Safety Set (SS), 105 subjects were treated with Vimpat at Baseline are included in this analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tablet</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oral Solution</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Galenic Formulation Repartition in Subjects Treated by VIMPAT® at 3 Months</title>
        <description>VIMPAT is available as tablet and oral solution formulation in Belgium. The use of each galenic formulation will be presented with number of subjects by formulation.</description>
        <time_frame>3 months</time_frame>
        <population>Of the 192 subjects in the Safety Set (SS), 137 subjects had Vimpat daily dosing information available at the 3-month visit and are included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients Treated With VIMPAT® Prior to Enrollment</title>
            <description>Patients who started VIMPAT® treatment before enrollment.</description>
          </group>
          <group group_id="O2">
            <title>Patients Who Started VIMPAT® Treatment on/After Enrollment</title>
            <description>Patients who started VIMPAT® treatment on/after enrollment.</description>
          </group>
          <group group_id="O3">
            <title>Total Population</title>
            <description>Patients who started VIMPAT® treatment before enrollment and patients who started VIMPAT® on/after enrollment.</description>
          </group>
        </group_list>
        <measure>
          <title>Galenic Formulation Repartition in Subjects Treated by VIMPAT® at 3 Months</title>
          <description>VIMPAT is available as tablet and oral solution formulation in Belgium. The use of each galenic formulation will be presented with number of subjects by formulation.</description>
          <population>Of the 192 subjects in the Safety Set (SS), 137 subjects had Vimpat daily dosing information available at the 3-month visit and are included in this analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="63"/>
                <count group_id="O3" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tablet</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="63"/>
                    <measurement group_id="O3" value="137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oral Solution</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Galenic Formulation Repartition in Subjects Treated by VIMPAT® at 6 Months</title>
        <description>VIMPAT is available as tablet and oral solution formulation in Belgium. The use of each galenic formulation will be presented with number of subjects by formulation.</description>
        <time_frame>6 months</time_frame>
        <population>Of the 192 subjects in the Safety Set (SS), 154 subjects had Vimpat dosing data available at the 6-month visit and are included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients Treated With VIMPAT® Prior to Enrollment</title>
            <description>Patients who started VIMPAT® treatment before enrollment.</description>
          </group>
          <group group_id="O2">
            <title>Patients Who Started VIMPAT® Treatment on/After Enrollment</title>
            <description>Patients who started VIMPAT® treatment on/after enrollment.</description>
          </group>
          <group group_id="O3">
            <title>Total Population</title>
            <description>Patients who started VIMPAT® treatment before enrollment and patients who started VIMPAT® on/after enrollment.</description>
          </group>
        </group_list>
        <measure>
          <title>Galenic Formulation Repartition in Subjects Treated by VIMPAT® at 6 Months</title>
          <description>VIMPAT is available as tablet and oral solution formulation in Belgium. The use of each galenic formulation will be presented with number of subjects by formulation.</description>
          <population>Of the 192 subjects in the Safety Set (SS), 154 subjects had Vimpat dosing data available at the 6-month visit and are included in this analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tablet</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                    <measurement group_id="O2" value="67"/>
                    <measurement group_id="O3" value="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oral Solution</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Who Received Concomitant Antiepileptic Drug Treatment</title>
        <description>Concomitant antiepileptic drug (AED) treatments are defined as treatments which started after or at the date of the first administration of VIMPAT®.</description>
        <time_frame>From baseline to study termination (6 months)</time_frame>
        <population>Of the 192 subjects in the Safety Set (SS), 192 are included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients Treated With VIMPAT® Prior to Enrollment</title>
            <description>Patients who started VIMPAT® treatment before enrollment.</description>
          </group>
          <group group_id="O2">
            <title>Patients Who Started VIMPAT® Treatment on/After Enrollment</title>
            <description>Patients who started VIMPAT® treatment on/after enrollment.</description>
          </group>
          <group group_id="O3">
            <title>Total Population</title>
            <description>Patients who started VIMPAT® treatment before enrollment and patients who started VIMPAT® on/after enrollment.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Who Received Concomitant Antiepileptic Drug Treatment</title>
          <description>Concomitant antiepileptic drug (AED) treatments are defined as treatments which started after or at the date of the first administration of VIMPAT®.</description>
          <population>Of the 192 subjects in the Safety Set (SS), 192 are included in this analysis.</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.1"/>
                    <measurement group_id="O2" value="96.6"/>
                    <measurement group_id="O3" value="97.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Persistence of VIMPAT® After 6 Months</title>
        <description>Treatment persistence is defined as the percentage of subjects being treated under VIMPAT® after a given duration (&gt;=6 months).</description>
        <time_frame>&gt;=6 months</time_frame>
        <population>Of the 192 subjects in the Safety Set (SS), 192 are included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients Treated With VIMPAT® Prior to Enrollment</title>
            <description>Patients who started VIMPAT® treatment before enrollment.</description>
          </group>
          <group group_id="O2">
            <title>Patients Who Started VIMPAT® Treatment on/After Enrollment</title>
            <description>Patients who started VIMPAT® treatment on/after enrollment.</description>
          </group>
          <group group_id="O3">
            <title>Total Population</title>
            <description>Patients who started VIMPAT® treatment before enrollment and patients who started VIMPAT® on/after enrollment.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Persistence of VIMPAT® After 6 Months</title>
          <description>Treatment persistence is defined as the percentage of subjects being treated under VIMPAT® after a given duration (&gt;=6 months).</description>
          <population>Of the 192 subjects in the Safety Set (SS), 192 are included in this analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.2"/>
                    <measurement group_id="O2" value="56.3"/>
                    <measurement group_id="O3" value="77.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects by Category of Clinical Evolution of Seizure Control at Baseline</title>
        <description>This outcome will be only provided for subjects who were already treated by VIMPAT® at Baseline.
Clinical evolution of seizures following administration of VIMPAT compared to baseline before start of VIMPAT. The evolution of seizure control is subjectively assessed by the investigator on a four categorical scale, with options being 1=worsened, 2=stable, 3=improved, 4=much improved. If seizure control is worse, the investigator will try to document the reason.</description>
        <time_frame>Baseline</time_frame>
        <population>Of the 192 subjects in the Safety Set (SS), 105 subjects were treated with Vimpat at Baseline are included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients Treated With VIMPAT® Prior to Enrollment</title>
            <description>Patients who started VIMPAT® treatment before enrollment.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects by Category of Clinical Evolution of Seizure Control at Baseline</title>
          <description>This outcome will be only provided for subjects who were already treated by VIMPAT® at Baseline.
Clinical evolution of seizures following administration of VIMPAT compared to baseline before start of VIMPAT. The evolution of seizure control is subjectively assessed by the investigator on a four categorical scale, with options being 1=worsened, 2=stable, 3=improved, 4=much improved. If seizure control is worse, the investigator will try to document the reason.</description>
          <population>Of the 192 subjects in the Safety Set (SS), 105 subjects were treated with Vimpat at Baseline are included in this analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Much Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Worsened</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects by Category of Clinical Evolution of Seizure Control at 3 Months</title>
        <description>Clinical evolution of seizures following administration of VIMPAT compared to baseline before start of VIMPAT. The evolution of seizure control is subjectively assessed by the investigator on a four categorical scale, with options being 1=worsened, 2=stable, 3=improved, 4=much improved. If seizure control is worse, the investigator will try to document the reason.</description>
        <time_frame>3 months</time_frame>
        <population>Of the 192 subjects in the Safety Set (SS), 152 subjects had Vimpat daily dosing information available at the 3-month visit and are included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients Treated With VIMPAT® Prior to Enrollment</title>
            <description>Patients who started VIMPAT® treatment before enrollment.</description>
          </group>
          <group group_id="O2">
            <title>Patients Who Started VIMPAT® Treatment on/After Enrollment</title>
            <description>Patients who started VIMPAT® treatment on/after enrollment.</description>
          </group>
          <group group_id="O3">
            <title>Total Population</title>
            <description>Patients who started VIMPAT® treatment before enrollment and patients who started VIMPAT® on/after enrollment.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects by Category of Clinical Evolution of Seizure Control at 3 Months</title>
          <description>Clinical evolution of seizures following administration of VIMPAT compared to baseline before start of VIMPAT. The evolution of seizure control is subjectively assessed by the investigator on a four categorical scale, with options being 1=worsened, 2=stable, 3=improved, 4=much improved. If seizure control is worse, the investigator will try to document the reason.</description>
          <population>Of the 192 subjects in the Safety Set (SS), 152 subjects had Vimpat daily dosing information available at the 3-month visit and are included in this analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="74"/>
                <count group_id="O3" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Much improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7"/>
                    <measurement group_id="O2" value="16.2"/>
                    <measurement group_id="O3" value="16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.6"/>
                    <measurement group_id="O2" value="33.8"/>
                    <measurement group_id="O3" value="38.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.6"/>
                    <measurement group_id="O2" value="35.1"/>
                    <measurement group_id="O3" value="34.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Worsened</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1"/>
                    <measurement group_id="O2" value="9.5"/>
                    <measurement group_id="O3" value="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5.4"/>
                    <measurement group_id="O3" value="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects by Category of Clinical Evolution of Seizure Control at 6 Months</title>
        <description>Clinical evolution of seizures following administration of VIMPAT compared to baseline before start of VIMPAT. The evolution of seizure control is subjectively assessed by the investigator on a four categorical scale, with options being 1=worsened, 2=stable, 3=improved, 4=much improved. If seizure control is worse, the investigator will try to document the reason</description>
        <time_frame>6 months</time_frame>
        <population>Of the 192 subjects in the Safety Set (SS), 168 subjects had Vimpat dosing data available at the 6-month visit and are included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients Treated With VIMPAT® Prior to Enrollment</title>
            <description>Patients who started VIMPAT® treatment before enrollment.</description>
          </group>
          <group group_id="O2">
            <title>Patients Who Started VIMPAT® Treatment on/After Enrollment</title>
            <description>Patients who started VIMPAT® treatment on/after enrollment.</description>
          </group>
          <group group_id="O3">
            <title>Total Population</title>
            <description>Patients who started VIMPAT® treatment before enrollment and patients who started VIMPAT® treatment on/after enrollment.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects by Category of Clinical Evolution of Seizure Control at 6 Months</title>
          <description>Clinical evolution of seizures following administration of VIMPAT compared to baseline before start of VIMPAT. The evolution of seizure control is subjectively assessed by the investigator on a four categorical scale, with options being 1=worsened, 2=stable, 3=improved, 4=much improved. If seizure control is worse, the investigator will try to document the reason</description>
          <population>Of the 192 subjects in the Safety Set (SS), 168 subjects had Vimpat dosing data available at the 6-month visit and are included in this analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="168"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Much improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.9"/>
                    <measurement group_id="O2" value="19.2"/>
                    <measurement group_id="O3" value="19.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.8"/>
                    <measurement group_id="O2" value="38.4"/>
                    <measurement group_id="O3" value="36.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.0"/>
                    <measurement group_id="O2" value="34.2"/>
                    <measurement group_id="O3" value="37.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Worsened</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3"/>
                    <measurement group_id="O2" value="8.2"/>
                    <measurement group_id="O3" value="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events (AEs) were collected during the course of the trial, which was approximately 2 years.</time_frame>
      <desc>Adverse Events refer to the Safety Set (SS). The Safety Set (SS) consisted of all subjects who were randomized and received at least 1 dose of study medication.</desc>
      <group_list>
        <group group_id="E1">
          <title>Vimpat® Treatment</title>
          <description>Reported Adverse Events is a combination of both patients who started VIMPAT® treatment before enrollment and patients who started VIMPAT® treatment on/after enrollment.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (9.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Eosinophilia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Meningitis herpes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Status epilepticus</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (9.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Gastrointestinal hypermotility</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia oral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Increased appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Dysphasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Facial paresis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>VIth nerve paralysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Abnormal dreams</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Depressive symptom</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Acute stress disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Aggression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Conduct disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Decreased interest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Initial insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Middle insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Obsessive-compulsive disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Sleep walking</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>UCB has &gt; 60 but &lt;= 180 days to review results communications prior to public release and may delete information that is confidential and compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that the results shall be published regardless of outcome.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>UCB (Study Director)</name_or_title>
      <organization>UCB Clinical Trial Call Center</organization>
      <phone>+1 887 822 9493</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

